STAT+: Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients
CHICAGO — The cancer drug Enhertu cut the rate of death in a group of women with advanced breast cancer by a third in a new clinical trial, a result that oncologists said could shift the way they think about treating the disease.
The makers of the medicine, Daiichi Sankyo and AstraZeneca, said that, if regulators clear the way, the number of patients eligible to receive the drug could be tripled, meaning that thousands of women in the U.S. alone could be offered a new life-extending option.
